Asia-Pacific Respiratory Syncytial Virus (RSV) Market to 2028 – Featuring AstraZeneca, Bavarian Nordic & Enanta Pharmaceuticals Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028” report has been added to ResearchAndMarkets.com’s offering.

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.

The Respiratory Syncytial Virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from US$36.88m in 2018 to US$1.48bn by 2028 across the five growth markets (*5GM – Australia, India, Japan, South Korea and urban China) in the Asia-Pacific (APAC) region. The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.

It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections. However, the global impact of new products in reducing the overall Respiratory Syncytial Virus (RSV) burden will depend on the cost-effectiveness of these drugs, as well as how vaccines are eventually integrated into national immunization policies throughout the 5GM – Australia, India, Japan, South Korea and urban China.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Asia-Pacific RSV market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Respiratory Syncytial Virus: Executive Summary

1.1 Strong Growth Projected for the RSV Market from 2018 to 2028

1.2 Both Large and Small Developers Are Focused on the Untapped RSV Therapeutics Market

1.3 The Market for Cost-Effective Prophylaxis Is Highly Competitive

1.4 Despite Projected Entrance of Novel Products, Opportunities Remain for Current and Future Players

1.5 Future RSV Management Strategies Will Include Multiple Products

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources Used and Not Used

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for RSV Hospitalized Population (2018-2028)

4.5.1 Number of Hospitalized Adults with Positive RSV Test

4.5.2 Number of Children Hospitalized for Confirmed RSV

4.6 Epidemiological Forecast for RSV Prophylactic Population (2018-2028)

4.6.1 Number of Preterm Births by Gestational Age

4.6.2 Preterm Infants with CLD

4.6.3 Number of Live Births with Hemodynamically Significant Heart Disease

4.6.4 Diagnosed Prevalent Cases of DMD

4.6.5 Number of Diagnosed Prevalent Cases of SMA

4.6.6 Number of Third Trimester Pregnant Women

4.6.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions

4.7 Discussion

5 Current Treatment Options

6 Unmet Needs and Opportunity Assessment in Asia-Pacific

6.1 Overview

6.2 Improved Cost-Effective Passive Prophylaxis

6.3 Prophylactic Vaccines

6.4 Effective Antivirals

7 R&D Strategies in Asia-Pacific

7.1 Overview

7.1.1 Leveraging Novel Vaccine Technologies and Strategies

7.1.2 Development of Prophylactic Antibodies with Improved Dosing and Efficacy

7.1.3 Development of RSV Antiviral Therapeutics with Diverse Mechanisms of Action

7.2 Clinical Trials Design

7.2.1 Clinical Trials Design of Pipeline Prophylactics for Maternal Immunization

7.2.2 Clinical Trials Design of Pipeline Prophylactics for Pediatric Immunization

7.2.3 Clinical Trials Design of Pipeline Prophylactics for Adult Immunization

7.2.4 Demonstration of Efficacy for Fusion Inhibitor Antivirals

7.2.5 Demonstration of Efficacy for Replication Inhibitor Antivirals

8 Pipeline Assessment in Asia-Pacific

8.1 Overview

8.2 Innovative Early-Stage Approaches

8.3 Other Drugs in Development

9 Pipeline Valuation Analysis

10 Appendix

Companies Mentioned

• Ark Biosciences
• AstraZeneca
• Bavarian Nordic
• Enanta Pharmaceuticals
• GlaxoSmithKline
• Janssen
• Merck & Co.
• Novavax
• Pfizer
• Pulmocide
• ReViral

For more information about this report visit https://www.researchandmarkets.com/r/9lr23m

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900